(Date:10/10/2008)...ng point for behavior change, DES MOINES, Iowa, O...,Americans (51 percent) believe there are good thi...r changes are needed, according to the 2008,EBRI H...oday by the,Employee Benefit Research Institute an...derwritten by the Principal Financial Group(R)., ...
(Date:10/10/2008)...dentialing Center (ANCC) has designated Geisinger ...s came via a conference call to hospital administr...and applause., GMC joins an elite group of only 1...n the United States that have achieved Magnet stat...s recognition., "Achieving Magnet designation is ...
(Date:10/10/2008)... blame , , FRIDAY, Oct. 10 (HealthDay Ne...ve diabetes, being depressed was associated with a..., Publishing in the October issue of the Journal...he University of Washington tracked 10,704 Medicar...d diabetes and were enrolled in a disease manageme...
(Date:10/10/2008)...llence in the implementation of electronic health ...agement Systems Society (HIMSS) announces the reci...onal, Ambulatory and Community Health Organization...L (PRWEB) October 10, 2008 -- Honoring excellence ... (EHRs), the Healthcare Information and Managemen...
Breaking Medicine News(10 mins):Health News:Video: Just What the Doctor Ordered: Survey Shows Americans Adopting Healthier Lifestyles 2Health News:Video: Just What the Doctor Ordered: Survey Shows Americans Adopting Healthier Lifestyles 3Health News:Geisinger Medical Center earns prestigious Magnet designation 2Health News:Older Diabetics With Depression Face Higher Death Rate 2Health News:2008 HIMSS Davies Awards: Nation's Outstanding Healthcare Organizations Recognized 2Health News:2008 HIMSS Davies Awards: Nation's Outstanding Healthcare Organizations Recognized 3Health News:2008 HIMSS Davies Awards: Nation's Outstanding Healthcare Organizations Recognized 4Health News:2008 HIMSS Davies Awards: Nation's Outstanding Healthcare Organizations Recognized 5...versity of Pennsylvania report the first ever use ... multiple body organs.// Mucopolysaccharidosis VII... called lysosomal storage diseases. Other examples...PS involves an enzyme defect, leading to blindness...
...e new high-tech abortion drug being freely sold ov...f do-it-yourself-abortions,// experts fear. Alread...tives, they claim, and even as the pharmaceutical ...ar meals ostensibly to introduce them to “the revo...
...gh discovery, American researchers have found some...pond to stimuli in the womb. There have always bee...mens such as 'hothousing',// where the baby is rea...he womb. However, the effectiveness of inventions...
...emical Laboratory (NCL) and Emcure Pharmaceuticals...ith a new drug for the treatment of hypertension. ...sday,// NCL director Sivaram and Emcure managing d...odipine, a product of their collaborative research...
Other Medicine News:Health News:Abortion made easy pill causes alarm in state 2(Date:10/8/2008)..., France, Oct. 8 /- Vical Incorporate...inical data and new nonclinical data,demonstrating...roadly,applicable in DNA- and protein-based infect...cines. Alain P. Rolland, Pharm.D., Ph.D., Vical,s,... present the data today,Wednesday, October 8, at ...
(Date:10/7/2008)...aluates the efficacy of new device for detecting p...ing colonoscopy, ORLANDO, Fla., Oct. 7 /PRNewswir...Annual Scientific Meeting in Orlando (ACG 2008), r...ented results from a,multi-institutional clinical ...(R) Retroscope(R), a new device that is designed t...
(Date:10/7/2008)...Showed Larazotide Acetate Prevented Immunologic Ch...s with Celiac Disease, Additional Data Indicates P...ORLANDO, Fla., Oct. 7 /- Alba Therape...cal studies this week at the American,College of G...ng. Data from,study CLIN 1001-004, the first Phase...
(Date:10/7/2008)... - Data Presented Today at ACG Annual Scientific M...Call/ -- Ironwood,Pharmaceuticals, Inc. (formerly ...E: FRX ) today announced the presentation of resu...safety and efficacy in 420 patients with,irritable...s of the data,indicates that once- daily oral dosi...
Breaking Medicine Technology:Vical Expands Applications of Vaxfectin(R) Adjuvant for Infectious Disease and Cancer Vaccines; 80% to 100% of High-Dose Responders in H5N1 Clinical Trials Still Responding at 6 Months 2Vical Expands Applications of Vaxfectin(R) Adjuvant for Infectious Disease and Cancer Vaccines; 80% to 100% of High-Dose Responders in H5N1 Clinical Trials Still Responding at 6 Months 3Vical Expands Applications of Vaxfectin(R) Adjuvant for Infectious Disease and Cancer Vaccines; 80% to 100% of High-Dose Responders in H5N1 Clinical Trials Still Responding at 6 Months 4Vical Expands Applications of Vaxfectin(R) Adjuvant for Infectious Disease and Cancer Vaccines; 80% to 100% of High-Dose Responders in H5N1 Clinical Trials Still Responding at 6 Months 5National Study Presented at ACG 2008 Confirms New Device Functions Like 'Rear-View Mirror' to Provide Improved View of the Colon 2National Study Presented at ACG 2008 Confirms New Device Functions Like 'Rear-View Mirror' to Provide Improved View of the Colon 3National Study Presented at ACG 2008 Confirms New Device Functions Like 'Rear-View Mirror' to Provide Improved View of the Colon 4National Study Presented at ACG 2008 Confirms New Device Functions Like 'Rear-View Mirror' to Provide Improved View of the Colon 5Alba Therapeutics Presents New Data for Larazotide Acetate at the 2008 American College of Gastroenterology Annual Scientific Meeting 2Alba Therapeutics Presents New Data for Larazotide Acetate at the 2008 American College of Gastroenterology Annual Scientific Meeting 3Alba Therapeutics Presents New Data for Larazotide Acetate at the 2008 American College of Gastroenterology Annual Scientific Meeting 4Alba Therapeutics Presents New Data for Larazotide Acetate at the 2008 American College of Gastroenterology Annual Scientific Meeting 5Alba Therapeutics Presents New Data for Larazotide Acetate at the 2008 American College of Gastroenterology Annual Scientific Meeting 6Ironwood and Forest Present Positive Phase 2b Study Results for Linaclotide in Patients With Irritable Bowel Syndrome With Constipation 2Ironwood and Forest Present Positive Phase 2b Study Results for Linaclotide in Patients With Irritable Bowel Syndrome With Constipation 3Ironwood and Forest Present Positive Phase 2b Study Results for Linaclotide in Patients With Irritable Bowel Syndrome With Constipation 4Ironwood and Forest Present Positive Phase 2b Study Results for Linaclotide in Patients With Irritable Bowel Syndrome With Constipation 5AMERIGROUP Corporation to Host Investor Day 1320 1AMERIGROUP Corporation to Host Investor Day 1320 2Amylin Pharmaceuticals to Webcast Corporate Overview During 43rd Annual Meeting of the European Association for the Study of Diabetes 1317 1Monsanto Company Signs Share Subscription Agreement With Devgen 594 1Monsanto Company Signs Share Subscription Agreement With Devgen 594 2Monsanto Company Signs Share Subscription Agreement With Devgen 594 3Non Stick Gum Something to Chew On 1313 1...27, 2007 /PRNewswire/ -- Afid,Therapeutics, Inc. a...ability of its new triple mode viral sequestration...ls. The audited results were,obtained from a speci...on. The new viral sequestrating agents are designe...hanisms thus blocking,infection. They are aimed at...
...NESS WIRE)--Mar 26, 2007 - CombinatoRx,Incorporat...lts of,a phase 2 clinical trial studying CRx-139 (...the antidepressant paroxetine),and 3mg prednisolon...). This trial served two important purposes. One p...isolone alone (a very low dose),in RA and to contr...
Other Medicine Technology:Afid Therapeutics Obtains Positive Evaluation of its Triple Mode,Viral Sequestration Agents 2CombinatoRx Provides Topline Results from Phase 2 RA Study with,CRx-139 and Very Low Dose Prednisolone 2CombinatoRx Provides Topline Results from Phase 2 RA Study with,CRx-139 and Very Low Dose Prednisolone 3CombinatoRx Provides Topline Results from Phase 2 RA Study with,CRx-139 and Very Low Dose Prednisolone 4CombinatoRx Provides Topline Results from Phase 2 RA Study with,CRx-139 and Very Low Dose Prednisolone 5CombinatoRx Provides Topline Results from Phase 2 RA Study with,CRx-139 and Very Low Dose Prednisolone 60.5 mm, 1 x 2 teeth set at 45 degrees and 6 mm tying platform. Serrated handle with polished finish.
5 mm tying platform, serrated cross action handle with polished finish. Teeth: 0.10 mm, 1 x 2 set at 90 degrees.
Colibri style tips with 0.12 mm, 1 x 2 teeth. Round knurled handle with alignment pin and polished finish.
0.12 mm, 1 x 2 teeth set at 45 degrees with 6 mm tying platform. Wide serrated handle with polished finish.
Medicine Products: